Marco Meglio

Minimal symptom expression, demonstrated by scores of 0 to 1 on MG-ADL, was observed in more than 25% of both rozanolixizumab groups compared with 3.0% of those on placebo.

More than 85% of the individuals who continued givosiran (Givlaari; Alnylam) through the 36-week open-label extension were attack free in the final 3 months of treatment.

From the pre-COVID period to 6 weeks after vaccination, the reporting rate of GBS was significantly different, regardless of whether Brighton criteria was applied to the analysis. The authors noted that passive surveillance limitations warrant further analysis.

After 12 weeks of treatment with zilucoplan 0.3 mg/kg, almost three-fourths of patients demonstrated at least a 3-point reduction in Myasthenia Gravis Activities of Daily Living scores.

The director of NYU Langone’s Alzheimer’s Disease Research Center and Center for Cognitive Neurology provided perspective on raising awareness for World Alzheimer’s Day and the ongoing challenges patients with the disease face.

After demonstrating a positive reduction of mutant huntingtin protein in preclinical studies, WVE-003 continued to show similar results when assessed in 30- and 60-mg doses.

One of the identified loci related to clinical progression in Parkinson disease expresses ADORA2A in the cerebellum, which encodes the adenosine A2A receptor, a promising target for therapeutics in PD.

The Parkinson disease agent showed a safe and tolerable profile, with significantly greater improvements in MDS-UPDRS-III scores and OFF time per day.

The explosion of new science and legislative decisions have expanded the capabilities and reach of newborn screening, providing thousands of families every year an opportunity to seek early, and critical, care for their infants.

Over a 2-year period, patients demonstrated improvements in Parkinson’s Disease Questionnaire scores, along with a 35% improvement in MDS-UPDRS-III scores.

Treatment with NurOwn resulted in response on several secondary outcomes, including timed 25-foot walk, 12-item multiple sclerosis walking scale, and low contrast letter acuity, among others.

Approximately half of the respondents with a history of headache screened positive for migrainous headache by ID-migraine criterion with most reporting moderate to severe intensity headache.

In addition to headache, other COVID-19 symptoms such as anosmia, myalgia, and nausea or vomiting were associated with higher survival rates.

Patients who demonstrated increased central pulse pressure and forward wave amplitude had greater entorhinal tau burden. These measures were not associated with amygdala, inferior temporal, nor precuneus tau burden.

Long-term use of the Constant Therapy program was feasible in a patient population with Alzheimer disease, as shown by the rate of adherence (80%) and use of the program over 24 weeks.

The molecular biologist at the Cleveland Clinic Lerner Research Institute discussed the unanswered questions regarding biomarkers sTREM2 and GFAP, and the role they play in Alzheimer pathology.

In a previous phase 2 study, patients treated with fosgonimeton alone demonstrated potentially beneficial change in ERP P300 latency, as well as cognitive improvement, compared with placebo at 26 weeks.

Infudopa SubC, or subcutaneous DIZ102, demonstrated 100% bioavailability compared with 80% for intestinal administration of levodopa/carbidopa gel infusion.

A doubling of mean seizure intervals was demonstrated from period 1 to period 4 for the 76-patient cohort who received the Neurelis nasal spray treatment across 360 days.

Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided commentary on an innovative approach using virtual reality to detect early signs of Parkinson disease.

Using patients with post–COVID-19 neurological symptoms, 90% of the cohort fulfilled the criteria for chronic fatigue syndrome, as expressed by the SOFA scale.

If approved, the oral fixed-dose coformulation of sodium phenylbutyrate-taurursodiol will become the third medication to receive an FDA greenlight for ALS.

In a recently submitted medical device report, Philips reported 14 serious injuries and 0 deaths related to the use of the recalled masks.

The substudy of the COVER-MS Project includes 300 patients with multiple sclerosis and will harness Quest Diagnostic’s national network of more than 2100 patient centers to provide periodic blood samples of immune responses to COVID-19 vaccines.

The molecular biologist at the Cleveland Clinic Lerner Research Institute provided commentary on how certain activity markers may help understand immune response differences in Alzheimer disease and related dementias.

Despite efforts to reduce perioperative complications rates by vetting of surgeons and sites, and refining patient selection, the findings nonetheless demonstrated no clinical benefit from the addition of stenting to medical therapy.

Stringent governmental measures predicted lower global scores on Pittsburgh Sleep Quality Index, while, albeit to a small extent, less restrictive measures were related to worse subjective sleep quality.

Among controls, there was a statistically significant difference of modified Rankin Scale scores between patients with and without atrial fibrillation, whereas no statistical difference was observed in the implantable loop recorder group.

Treatment with rimegepant, an FDA-approved treatment for acute and preventative migraine, resulted in decreases of more than 30% in monthly butalbital prescription fill and reductions of more than 25% in mean milligrams dispensed.

Compared with placebo, vamorolone-treated patients showed significantly better outcomes on several secondary and exploratory end points, such as the NorthStar Ambulatory Assessment and time to climb 4 stairs.